Drug Trial Radar · NCT01886378
A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Last checked: Nov 20, 2026Latest source record: Feb 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Feb 6, 2014
Primary completion
Aug 25, 2016
Study completion Aug 25, 2016
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment.
Conditions
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Carnitine Palmitoyltransferase (CPT II) Deficiency
- Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
- Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
- Trifunctional Protein (TFP) Deficiency
Interventions
UX007Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Time Adjusted-Area Under the Curve (AUC/Time) for Workload During Cycle Ergometry at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Time-Adjusted-AUC for Respiratory Exchange Ratio (RER) During Cycle Ergometry at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Actual Duration of Exercise During Cycle Ergometry at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Distance Traveled During the 12-Minute Walk Test (12MWT) at Week 18Time frame: Baseline (last assessment during the 4-week run-in period), Week 18
- Change From Baseline in Energy Expenditure Index (EEI) During the 12MWT at Week 18Time frame: Baseline (last assessment during the 4-week run-in period), Week 18
- Change From Baseline in Percentage of the Predicted 6-Minute Walk Test (6MWT) Distance Walked at Week 18Time frame: Baseline (last assessment during the 4-week run-in period), Week 18
- Change From Baseline in Physical Summary Score (PHS-10) of the Short Form 10 (SF-10) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Psychosocial Summary Score (PSS-10) of the SF10 at Week 24Time frame: Baseline, Week 24
- Change From Baseline in the Physical Component Summary Scale (PCS-12) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in the Mental Component Summary Scale (MCS-12) at Week 24Time frame: Baseline, Week 24
- Annualized Event Rate of All Major Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Duration Rate of All Major Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Event Rate of Major Rhabdomyolysis Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Duration Rate of Major Rhabdomyolysis Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Event Rate of Major Hypoglycemia Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Duration Rate of Major Hypoglycemia Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Event Rate of Major Cardiac Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
- Annualized Duration Rate of Major Cardiac Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Children's National Medical Center
Washington D.C., District of Columbia
University of Southern Florida
Tampa, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Vanderbilt Medical Center
Nashville, Tennessee
University of Utah
Salt Lake City, Utah
Birmingham Children's Hospital
Birmingham, United Kingdom
National Hospital for Neurology and Neurosurgery
London, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.